ONCOSCOPE
REAL-TIME ONCOLOGY LIBRARY

Stacy Grieve[1], Anna Forsythe[1], Saro Sarkisian[2]

[1]Oncoscope, Miami, FL, USA; [2]Frederick Health, Frederick, MD, USA

ISPOR Europe 2026
8-11 November 2026
Vienna, Austria

SA49

Anticipating future comparators in post-ICI NSCLC

A living evidence approach using real-time ai-assisted living systematic literature review (REAL-SLR)

BACKGROUND

The EU **Joint Clinical Assessment (JCA)** requires current, robust comparator evidence to support clinical effectiveness assessments. In advanced Non-Small-Cell Lung Cancer (NSCLC), treatment options following progression on immune checkpoint inhibitors (ICIs) remain limited. However, rapid expansion of novel therapeutic classes is creating an increasingly complex comparator landscape.

OBJECTIVES

To identify emerging comparator classes and inform evidence-generation and JCA planning in post-ICI NSCLC using the **Oncoscope REAL-SLR database.**

METHODS

A **PRISMA-compliant** REAL-SLR was conducted using **continuously updated** protocol-driven searches for advanced NSCLC. Interventional studies in metastatic NSCLC previously treated with ICIs were identified from publications and major conference abstracts and mapped according to clinical stage, treatment pathway, intervention category, and subgroup characteristics. US/EU regulatory status, guideline recommendations, and HTA-relevant treatment positioning supplemented evidence mapping. Studies were limited to primary publications from 2022 onward.

Table1. **Oncoscope REAL-SLR PICOS & JCA mapping**

PICOS	REAL-SLR PICOS	JCA Mapping
Patient population	Patients diagnosed with NSCLC at any stage	Disease stage: **metastatic NSCLC**; Histology: Any; Biomarker: Any; Treatment path: **prior immune checkpoint inhibitors**
Interventions and Comparators	Any intervention used for the treatment of NSCLC (surgery, radiotherapy, drugs, biologics, cell treatments, vaccines, etc.)	Same as REAL-SLR PICOS
Outcomes measures	Efficacy (OS, PFS, other progression, response), PROs, safety	Same as REAL-SLR PICOS
Study design	RCTs, non-RCTs, single arm, Phase 1, Phase 1/2, Phase 2, Phase 2/3, Phase 3, Phase 4; Pooled analyses of RCTs; ECTs	Same as REAL-SLR PICOS
Other limits		**Exclusion** of approved/recommended therapies and failed trials

KEY TAKEAWAYS

Oncoscope REAL-SLR database IDENTIFIED emerging treatment classes with the potential to become FUTURE COMPARATORS in post-ICI NSCLC.

Continuous evidence monitoring may support EARLIER IDENTIFICATION of comparator shifts, REDUCE RISK of evidence-generation, and IMPROVE PREPAREDNESS for JCA, HTA, and reimbursement decision-making in rapidly evolving oncology indications.

Figure 1. **Continuously updated PRISMA (REAL-SLR framework) in NSCLC (updated Sep 10, 2026)**



Figure 2. **Emerging comparator landscape in post-ICI NSCLC**

186
STUDIES MAPPED
as of September 10, 2026

Most **ADC** and **bispecific** programs were designed to enhance or restore anti-tumor immune responses

20.7%
of ADC studies targeted immune checkpoint proteins

76.5%
of bispecific studies evaluated agents with both binding domains interacting with the immune system



Table 2. **Development phase of identified studies**

Phase of trials	Studies, n (%)
Phase 1	**96** (51.6)
Phase 2	**75** (40.3)
Phase 3	**8** (4.3)
Not reported	**7** (3.8)

Figure 3. **Disease map of investigational interventions in mNSCLC with prior ICI**



View all Oncoscope posters at ISPOR Europe 2026

ABBREVIATIONS

ADC, antibody-drug conjugate; **ECT**, externally controlled trial; **EU**, European Union; **HTA**, health technology assessment; **ICI**, immune checkpoint inhibitor; **JCA**, Joint Clinical Assessment; **mNSCLC**, metastatic NSCLC; **NCCN**, National Comprehensive Cancer Network; **NSCLC**, non-small-cell lung cancer; **OS**, overall survival; **PFS**, progression-free survival; **PICOS**, population, intervention, comparator, outcomes, and study design; **PRISMA**, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; **PRO**, patient-reported outcome; **QoL**, quality of life; **RCT**, randomized controlled trial; **REAL-SLR**, Real-Time AI-Assisted Living Systematic Literature Review; **SLR**, systematic literature review; **US**, United States.